Professor Uhm Sung Ho's laboratory team reported innovative ways to improve lung cancer diagnosis
- 공과대학
- Hit5872
- 2019-06-24
Professor Uhm Sung Ho's laboratory team
reported innovative ways to improve lung cancer diagnosis
Lung cancer diagnosis was not only expensive but also took about three weeks.
Now available with lower price and 3 hours of extracorporeal diagnosis.
Propose new indicators for future disease prevention and customized treatment
through simultaneous determination of multiple genes
A team of researchers led by Uhm Sung-ho, a professor at the school of chemical engineering, and a team of researchers led by Ahn Myung-joo, a professor at the Department of Blood Cells at medical school, said they have found ways to dramatically improve lung cancer diagnosis. The lung cancer examination, which used to cost about three weeks, was made possible by in vitro diagnosis within three hours due to low prices, and is expected to contribute greatly to lung cancer screening and treatment. The study was conducted with full support from the post-genome multi-department dielectric project in the health and medical technology R&D project hosted by the Ministry of Health and Welfare, and was selected as a cover painting of 'Advanced Biosystems', the highest authority in the field of multidisciplinary science, and published in an online edition on June 14.
The research team developed high-performance nucleic acid nano-structure-graphin oxide to realize high-speed, real-time, multiple diagnostics of certain genetic combinations of lung cancer diseases without PCR. The time required to diagnose cancer has been dramatically reduced and the method was applied to liquid biopsy, emerging as a noninvasive, patient-friendly cancer diagnosis. This opened up the simultaneous diagnostic method of multiple biomarkers of lung cancer applicable to liquid biopsies (early, late-stage, recurrent) lung cancer treatment models for the first time.
The institute, which participated as the first author of the study, developed a selectively discriminating nucleic acid-structure platform that identifies the combination of specific micro RNA groups known as cancer cell fingerprint genes that contain information on the progression of normal cells to cancer cells and epithelial growth factor receptor (EGFR) gene variations in lung cancer cases. The platform also enables the distinction of point mutations, which show the difference between one single gene mutation. In addition, multiple biomarkers will be identified within three hours, taking a step closer to diagnosing hyperprecision cancer (especially lung cancer).
Changes in specific genes or changes in the rate of expression of genetic material are thought to affect the occurrence and progression of cancer. In the case of lung cancer, EGFR gene variation is typical, and between 35 and 50 percent of Asian patients are affected. Recently, it has been studied that the development of micro RNA directly affects the production of cancerous tumors, and this has drawn great attention. In order to detect these genes, the target bio-samples, need to be secured in an invasive. surgical manner. This causes significant physical and mental pain for the patient and the use of technology is quite limited depending on the location of the tumor. Furthermore, the genetic testing process takes weeks to complete even after the tissue has been collected. Therefore, a patient-friendly diagnostic method is urgently needed to evaluate patient's drug suitability and resistance in a comprehensive way. In this study, a high-speed diagnostic platform applied to blood was developed. Verification of variation in the EGFR gene can be actively used in prescribing therapeutic agents, and simultaneous identification of micro RNA groups will greatly contribute to the discovery of new cancer biomarkers and the establishment of treatments.
The research team built a nanobar-coding platform system as a new nano-hybrid material between the fluorescent nucleic acid biomolecules and the graphene oxide. The system is designed to selectively react with micro RNA originating from lung cancer and its specific genetic biomarkers, and is designed to enable certain fluorescent switches to react and turn on themselves in the presence of certain biomarkers. This can be applied to a variety of genetic biomarkers at the same time and can be used in various ways, including gene diagnosis and in prevention kits, in clinical trials. In fact, it addressed the potential for precision medicine for the first time by addressing the comprehensive challenges of clinical kits, and this reagents platform is being commercialized from DNANO (CEO: Choi Yoo-jung) to the name FluorographTM.
Professor Eom Sung-ho said, "The reduced examination time and applicability to liquid biopsy are realized by enabling real-time monitoring of drug efficacy in combination with rapid treatment prescription in actual clinical diagnosis. It will be commercialized and evolve into a form like a pregnancy kit, providing convenience for health and welfare in everyday life as soon as possible.